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No man is an island, 
Entire of itself, 
Every man is a piece of the continent, 
A part of the main. 
If a clod be washed away by the sea, 
Europe is the less. 
As well as if a promontory were. 
As well as if a manor of thy friend's 
Or of thine own were: 
Any man's death diminishes me, 
Because I am involved in mankind, 
And therefore never send to know for whom the bell tolls;  
It tolls for thee. 
John Donne 1572-1631 
   
 
 
 
To my one and only, my soulmate, my love and my husband, Mårten
  
ABSTRACT 
Introduction  
Patients with paroxysmal atrial fibrillation often experience impaired health-related 
quality of life. Standard treatment is not always sufficient and changes in life-style 
habits are suggested as a complement. Also, studies have suggested differences in 
gender where women have extended side effects of rhythm medications, more 
symptoms and estimate lower health-related quality of life than men. Yoga has been 
shown to increase health-related quality of life and decrease blood pressure, heart 
rate and cardiac biomarkers. The overall aim of this thesis was to study the effects of 
MediYoga among patients with paroxysmal atrial fibrillation. In addition, to evaluate 
perceptions and experiences of MediYoga as well as gender differences.  
Methods and results 
 
Paper I: This is a randomized, controlled pilot study in which 80 patients were 
randomized to MediYoga, n=40, or a control group, n=40 at an University Hospital, in 
Stockholm, Sweden. The yoga groups had been performing MediYoga for one 
hour/week over a 12 weeks period. Assessments as health-related quality of life  
questionnaires (i.e. SF-36, EQ-5D Visual Analogue Scale), blood pressure and heart 
rate were collected at baseline and at the end of study. The results showed an 
improvement of health-related quality of life in the yoga group. Blood pressure and 
heart rate also decreased in the yoga group. 
 
Paper II: In this prospective randomized study at an University Hospital, Stockholm, 
Sweden, with stratification in gender, 132 patients, with symptomatic PAF, were 
randomized to yoga (n=44), relaxation (n=44) and a control group (n=44). The yoga 
groups had been performing MediYoga for one hour/week over a 12 weeks period. 
Assessments as health-related quality of life questionnaires (i.e. SF-36, ASTA), 
blood pressure, heart rate as well as NT-proBNP were collected at baseline and at 
the end of the study. The results showed no differences in the ASTA and SF-36 
between the groups. However, improvements were seen in health-related quality of 
life, SF-36, with-in the MediYoga group. Both systolic and diastolic blood pressure 
decreased in the MediYoga group compared to the control group but there was no 
difference compared to the relaxation group. There were no differences in heart rate 
and NT-proBNP between or with-in the groups after 12 weeks. 
Paper III: A study with a qualitative design was conducted using individual semi-
structured interviews. The study included 12 participants (7 men and 5 women) who 
had participated in the yoga group in Paper II. The data were analysed using 
qualitative content analysis with an inductive method and a manifest approach. 
Three categories were found in the analysis; “A time for a sense of existence and 
presence”, “A way of gaining well-being and increased consciousness” and “Access 
to a tool to gain willpower and relieve symptoms”. 
 
 Paper IV: A comparative design examining gender differences among those who 
had performed MediYoga (women n=37, men n=34). The yoga groups had been 
performing MediYoga for one hour/week over a 12 weeks period. Data (i.e health-
related quality of life [SF-36], blood pressure and heart rate) were collected at 
baseline and the end of the study. There were no differences between the women or 
men group in SF-36 at end of study, however, there was improvement with-in the 
women group in the subscales vitality, social function, mental health and the domain 
mental component summary score. In the male group, there were improvement with-
in the subscales role-physical, bodily pain, general health, vitality, social function, 
role-emotion and the domain mental component summary score (SF-36). There 
were no differences between the groups in systolic and diastolic blood pressure as 
well as heart rate at the end of the study. With-in the women group differences were 
observed in systolic and diastolic blood pressure, however, no difference was seen 
in heart rate. With-in the men group improvement were seen in diastolic blood 
pressure but no differences were seen in systolic blood pressure or heart rate. 
Conclusions  
MediYoga improves health-related quality of life as well as blood pressure among 
patients with PAF. Also, both genders report benefits, and patients describe 
MediYoga as an accessible tool with which to handle emotions and symptoms. 
MediYoga may be a part of a self-management program, as a complementary 
treatment, among patients with PAF. 
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BACKGROUND 
 
ATRIAL FIBRILLATION 
 
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the adult population 
and the median age of onset is approximately 75 years (1). Patients with AF have an 
increased cardiovascular morbidity, including stroke and mortality (2). There are 
different types of atrial fibrillation: paroxysmal (PAF; usually short episodes of 
fibrillation which spontaneously converts [within 7 days] to normal heart rhythm), 
persistent (requires treatment to convert to a normal heart rhythm) and permanent 
(chronic). Because of the difference in the presentation and duration of episodes of AF, 
five categories have been identified, i.e. first diagnosed, paroxysmal, persistent, long-
standing persistent, and permanent AF. PAF usually develops into permanent AF over 
time and AF is often characterized by a rapid and irregular rhythm (2).  
Prevalence 
 
The prevalence rate of AF, in the adult population, is internationally considered to be 
more than three percent. However, it is difficult to calculate the exact prevalence rate 
as many patients have silent AF, which is thus undetected (3). In an AF population, 
about one-fourth has PAF and these patients are younger and have a lower incidence 
of heart disease AF (4).  
 
Pathophysiology and risk factors 
AF consists of multiple re-entry circuits in the atria causing a chaotic rhythm, which 
over time is believed to cause so-called remodelling and fibrosis, often due to ageing. 
In younger patients, the mechanism is less clear (5). The resulting atrial rhythm 
becomes chaotic and rapid, up to 600 beats per minute. In this situation the AV node 
acts as a filter and reduces the number of beats reaching the ventricle (5), Figure I.  
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Figure I. Pictures imaging normal heart beat and heart beat in atrial fibrillation 
Owner of illustration Maria Wahlström 
 
Factors which increase the risk of the developing of AF (6-10) are shown in Table I. 
Apart from age and gender, hypertension is the most significant risk factor. Moreover, 
an increased left atrial size (11), inflammatory markers (12) as well as diabetes mellitus 
(13) are associated to the incidence of AF. Hyperthyroidism increases systolic blood 
pressure (SBP) and heart rate (HR) and is also a risk factor in the incidence of AF (14). 
Moreover, there is a relationship between obesity and impaired diastolic heart function 
for the development of AF (15). Also, obesity are linked to an increased basal 
inflammatory status which in turn have an impact in the remodelling process of the 
atrium (16). Obstructive sleep apnoea has a role in atrial remodelling, sympathovagal 
imbalance, inflammation and oxidative stress in patients with AF (17). Several 
biomarkers, including N-terminal prohormone Brain Natriuetic Peptide (NT-proBNP) 
and troponin, are usually ascribed to cardiac damage as well as heart failure and have 
been shown to be related to AF. These markers also correlate to an increased risk of 
stroke and mortality in patients with AF (18). NT-proBNP is a cardiac biomarker which 
is released in response to the atrial myocyte stretch (19, 20). Moreover, psychosocial 
factors such as traumatic life events, especially in older women, stress at work as well 
as depression have been related to the incident AF (21-23). 
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Table I. Risk factors and diseases 
 
  Risk factor    Disease 
High age                         Hypertension 
Female gender                         Diabetes mellitus 
Smoking                         Thyroide disease 
Alcohol                         Heart failure 
High intensive training                        Acute and chronic heart disease 
Stress                        Sleep apnoea 
Obesity                        Chronic kidney disease 
 
Symptoms 
Symptoms are often present in the form of palpitations, chest tightness, 
shortness of breath, dizziness, anxiety and/or worry (24). A rapid ventricular 
heart rate, during the episode of AF, may contribute to a compromised cardiac 
output due to impaired diastolic filling, which may generate chest tightness as 
well as shortness of breath. Dizziness may be associated with an imbalance in 
the parasympathetic and sympathetic nervous system (25). However, in about a 
third of the AF population there are no symptoms, so-called silent atrial 
fibrillation. These patients might thus be undiagnosed and neglected with 
respect to anticoagulation treatment (3). 
Treatment 
The primary treatment goals, for patients with AF, are to relieve symptoms and 
decrease the risk of stroke (2). The standard treatment for relief of symptoms 
consists of rhythm- and rate medication, cardioversion as well as ablation. 
Ablation is increasingly used, but is not always effective and may cause serious 
adverse events in 2-3 percent (26). In addition, anticoagulants are offered to 
patients with an increased risk of stroke indicated by CHA2DS2VASc scores (2). 
As hypertension is a significant risk factor the management of AF should include 
an adequate blood pressure control to prevent the incident of stroke and other 
cardiovascular events (27). As current treatment regimes are often not effective, 
alternative approaches should be examined, for example, changes in lifestyle 
factors (28, 29). AF is known to be related to alcohol consumption (the “holiday-
heart”), thus reducing alcohol intake is an important part of possible life style 
changes (30). Loss of weight, in patients with high body mass index (BMI), 
reduces episodes of AF (31), and as a high BMI is the largest modifiable risk 
factor, weight reduction is an alternative component of treatment (32). Physical 
activity is generally beneficial to becoming healthy or maintaining health as well 
as in preventing cardiovascular mortality and morbidity (33).  
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Physical activity also helps to reduce the incidence of AF, where moderate-intensity 
exercise has been shown to be effective (34). However, a meta-analysis concluded 
that exercise, among adults with AF, showed no benefits regarding HRQoL (35). As 
current treatment strategies may involve changes in life-style, it is suggested that a 
tailored management of each individual with AF is integrated in clinical practice (36). 
Gender differences in AF 
More men (55 %) than women have AF in the population (37), and men have more 
persistent AF than PAF. Women, with AF, are older and have more hypertension as 
well as heart failure (38). Also, women have a lower incidence of other heart diseases 
than men (39). Moreover, women over 65 years with AF have also an increased risk of 
developing stroke (40). In addition, men seem to have a higher cardiovascular risk 
factor profile (41), such as hypertension, obesity and metabolic syndrome, which 
increases the risk of stroke (42). Regarding to treatment, women receive less 
cardioversion as well as more rate control medications than men (38). Also, women 
had more adverse effects of other treatments, as antiarrhythmic medications (43). 
However, the treatment strategies, in terms of gender, have over the years being 
improved (44). 
CARING 
In caring science, the health perspective is described as to "feel good and be in a 
position to implement what is considered to be of value in life" (45). The feeling that is 
linked to "health" is a general perception of well-being and the ability to perform certain 
tasks. This is connected not only to biological functions, but also to how we can 
manage our own existence based on our own experiences of life (45, 46). Health 
concerns both biological functions and existential issues, with both the presence and 
absence of disease affecting the possibility of experiencing well-being (46). Caring 
science also emphasizes the importance of viewing the patient as a whole, and not 
merely in terms of her/his disease. This holistic approach entails patients being able to 
see meaning, realise a context and perceive well-being based on their own perspective 
and experience. Moreover, the goals and overall objective in caring science is to 
support and strengthen patients’ health processes considering health, disease and 
suffering. This process should be based on the patient's perception of their context in 
life and how the disease affects the experience of meaning and context (45). In 
addition, according to Dahlberg et al. (47), patients have a desire to be seen as 
individuals in their personal context and need tools to deal with concerns in their own 
life-world caused by the disease. 
QUALITY OF LIFE AND HEALTH-RELATED QUALITY OF LIFE  
Health is defined by the World Health Organisation (WHO) as “a state of complete 
physical, mental and social well-being and not merely the absence of disease or 
infirmity” (48) and is an important aspect in quality of life (QoL). WHO defines QoL as 
“an individual's perception of their position in life in the context of the culture and value  
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systems in which they live and in relation to their goals, expectations, standards 
and concerns” (49). The concept QoL is complex, means different things to 
different people and may change over time. Moreover, there is no universally 
accepted definition. It can be described as a feeling of well-being, the need for 
satisfaction and happiness and the preservation of life and/or functionality (50). 
However, over the years, it has been generally accepted that the dimensions of 
physical, mental (emotional and cognitive), and social well-being should be 
included when measuring QoL (51).  
Health-Related QoL (HRQoL) is related to the definition of QoL. However, 
HRQoL should, in addition to general QoL, also include behavioural or function-
oriented dimensions, i.e. the patient’s capacity to fulfil everyday life roles (52). 
Additionally, the inclusion of mental health has been discussed, as an 
improvement in mental health seems to be connected with an improved physical 
health (53).  
Traditionally, health care has focused on clinical outcomes as primary 
measurement variables (54). However, measuring HRQoL may detect other 
aspects affecting patients, e.g. side effects of various treatments, which in turn 
may reduce HRQoL. In chronic conditions, this plays an important role, where the 
only possibility is to reduce symptoms. Moreover, it is important to evaluate the 
effect of various treatments. Therefore, evaluating HRQoL may influence 
decisions as to whether treatments should be initiated, maintained, changed or 
phased out (50). Thus, given the impact of the intervention/therapy on the 
patient’s well-being, it is important to validate HRQoL in clinical intervention 
studies (50). However, as HRQoL can be measured by general or disease 
specific assessments, it must be related to the study’s outcome (50). In addition, 
measuring HRQoL is a subjective appraisal, which might vary over time and 
seems be associated with coping strategies (55) and perceived sense of 
coherence (56).  
Health-related quality of life and atrial fibrillation 
It has been established that AF is associated with impaired HRQoL (57, 58) and, 
in addition, patients with AF report similar HRQoL scores as patients with other 
heart diseases (57). Episodic AF symptoms influence the patient’s social situation 
and working habits (59) with feelings of anxiety and depression often being 
present (60). Patients report that stress is a factor affecting the appearance of 
episodes of AF. This in turn reduces HRQoL (61). With regard to gender 
differences, women estimate overall scores of health status, psychological and 
mental domains and QoL lower than men (38, 62-64), which may be related to 
women experiencing more symptoms, such as palpitations and fear/anxiety.  
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Additionally, impaired HRQoL, in patients with AF, increases the number of 
hospitalizations (65). It is recommended, therefore, that forthcoming research on new 
treatment strategies should include patients´ assessments of HRQoL (57, 66). 
Moreover, there is a need for new interventions that support patients, regarding 
emotions during and/or between episodes of AF (67, 68). Additionally, there is a need 
to develop practical strategies, such as self-management, in order to counteract AF 
symptoms that limit daily living (68).  
There is sparse information about how to enhance HRQoL in patients with AF. A 
recent study concluded that a mindful-based cognitive behaviour therapy program 
increased HRQoL in patients with AF and was associated with a sense of coherence. 
This study evaluated patients together with spouses, and the program was conducted 
at a hospital with trained instructors (69). Moreover, structured care, with integrated 
nurse-led education about AF for the patients, seemed to improve HRQoL and 
decrease symptoms (70). 
SELF-CARE AND MANAGEMENT 
Orem’s self-care theory states that people are willing, and have the ability to, do 
whatever is necessary to prevent disease and promote their own health. They thus 
have a built-in motivation to implement actions for their own good (71, 72). This theory 
is based on the fact that if people have the knowledge and ability, they will take care of 
themselves. It is already used in today's health care in trying to help the patient to 
acquire independence, as well as increase QoL (73). However, this theory is intended 
to support nursing practice in caring for patients and is not directed, initially, at the 
patients.  
At the end of the last century, Riegel et al. developed a multidisciplinary disease 
management program (74). This has been further developed (75) as well as having 
been accepted as a middle-range theory of self-care in chronic illness (76). A middle-
range theory describes a limited number of variables and specific phenomena (77). 
This middle-range theory of self-care in chronic illness includes self-care maintenance, 
self-care monitoring and self-care management (76).  
Over the past few years the term self-management has been described and analysed 
in different contexts (78, 79). It is based on social cognitive theory (80), which involves 
knowledge of the specific disease, perceived self-efficacy, health goal setting and 
strategies to retain or improve health outcomes. Bandura proposes that “self-efficacy is 
a focal determinant because it affects health behaviour both directly and by its 
influence on the other determinants” (80). 
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However, self-management is not a straight forward concept, due to different 
definitions and applications. Self-management, in this context, may be defined 
as, “to be active in managing a disease” (78), (s.1) which, for many patients with 
chronic illness, may be a lifetime task. Lorig et al. describes three self-
management tasks; medical-, role- and emotional management. Medical tasks 
involve medical management of the conditions, such as dealing with a special 
diet and remembering to take medication as prescribed. Role management 
involves changing, creating or maintaining new behaviours or life roles. As a 
chronic disease may reveal emotions, such as anger, fear and depression, the 
final task, emotional management, is to learn to manage these emotions (78). 
Moreover, factors which affect self-management are personal lifestyle 
characteristics, health status, resources, environmental characteristics and 
health care system (81, 82).  
The literature describes various self-management programs among different 
diseases, such as heart diseases, asthma and pain (74, 81, 83-85). Those 
programs consist of education, monitoring symptoms, medical adherence, life-
style change etc., and are tailored, evaluated and conducted to address the 
challenges of the disease. In addition, web-based programs are suggested in 
order to increase self-care motivation and to support patients with AF, and are 
intended to have a positive impact on patients´ outcome and QoL (86).The 
European Society of Cardiology guidelines, 2016 (2), recommend an integrated 
approach to the management of AF, as well as making suggestions to nurses 
and health professionals as how to provide those interventions discussed and 
recommended (87). We have found only one study, currently in progress, which 
is evaluating a self-management program among patients with AF (88). This 
protocol includes education and behaviour change strategies for patients with 
AF.  
COMPLEMENTARY THERAPIES 
Complementary and alternative medicine have been described as forms of 
treatment that are outside traditional, established scientific realms of knowledge 
(89). Over the years, definitions have changed and complementary therapies 
have come to be regarded as an addition to traditional care. Alternative medicine 
is not conducted in concert with established care (89). There are many different 
kinds of complementary and alternative therapies (90) widely used in health-care 
in Australia (91), the USA (92) and UK (93). WHO states that the use of 
complementary medicine has increased significantly globally and that countries 
should evaluate and perhaps implement selected complementary therapies in 
health-care (94). 
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A recent review shows that patients with AF often seek alternative methods to alleviate 
their symptoms (95). In patients with persistent AF, acupuncture treatment prevents 
arrhythmic recurrences after cardioversion, when compared to amiodarone (96).  
Soft music therapy, as a complement to standard treatment, aims to reduce symptoms 
of anxiety, lower blood pressure and reduce heart rate after thoracic surgery (97). Also, 
music therapy has been shown to reduce anxiety and enhance well-being in patients 
during coronary angiography (98). A Cochrane analysis reports that music may 
achieve a better QoL, lower blood pressure and heart rate, improve sleep and reduce 
worry (99). However, these results should be viewed with caution as the studies 
involved different kinds of music and interventions.  
Mindfulness is characterized as complementary therapy and the concept is derived 
from yoga and may be described as a conscious in presence, awareness and actions 
(100). In a review, the authors concluded that mindfulness may reduce symptoms, 
both physical and mental, in combination with treatment in cancer, cardiovascular 
disease, depression and chronic pain (101). Another complementary therapy is 
transcendental meditation (TM), meditation with mantra, which has positive impact in 
blood pressure and is recommended by the American Heart Association (AHA), (102). 
This meditation technique is used in yoga, which is another complementary therapy. 
YOGA 
The word yoga is Sanskrit and is an integration of mind, body and soul. Yoga, 
described in the Vedas approximately 5,000 years ago, originates from India and was 
described in the West, for the first time, in the 19th century (103). The practising of a 
yoga consists of three components: movements, breathing techniques, and meditation 
(104). The primal yoga form, Ashtangayoga, has now been explored as an effective 
form of exercise (104). Hatha- and Kundaliniyoga are derived from Ashtangayoga 
(103). Hathayoga is a more meditative yoga form than Ashtangayoga and more 
physical than Kundaliniyoga. Kundaliniyoga is the most meditative form of yoga and is 
performed with calm movements, focused on breathing techniques and meditation. 
The first institute to evaluate the effect of yoga on bodily functions was the 
Kaivalyadhama Centre, India, in 1923. During the past ten years the number of 
published articles about yoga and its effects on health has increased threefold (105). 
Yoga as therapy  
Practicing yoga may contribute to calming biological functions and relieving stress 
(104), as well as improving the balance of the parasympathetic and sympathetic 
nervous systems (106). According to a review, yoga may improve risk factors, such as 
hypertension and hyperlipidaemia (107). In addition, heart rate decreased after 
performing yoga (108-110) and blood pressure in patients with hypertension (111, 
112). Breathing techniques, alternately slow and fast breathing, which are used in 
yoga, show positive effects on blood pressure (113).  
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A deep breathing technique also has a positive impact on hypertension (114-
116), although larger randomized studies are needed (117). In a small study, 
NT-proBNP decreased in patients with heart failure after practising yoga (118). 
In heart rehabilitation, yoga has been used as a therapeutic treatment, and has 
proved beneficial regarding blood pressure, hyperlipidaemia, heart rate and 
blood glucose (115, 116). In addition, yoga has had the same effects as 
standard treatment (physical exercise) in patients with chronic illness (e.g. heart 
disease and stroke) (114). In caring, nurses may advise patients with heart 
failure to practise yoga as self-care to improve their health (119).  
Yoga has been suggested as a way of increasing QoL in patients with heart 
failure (120, 121) and hypertension (111). Moreover, depression and anxiety 
decreased in patients with symptomatic PAF after performing yoga (109) as well 
as in patients with hypertension (122). Positive effects of yoga on QoL have 
been described in the treatment of other conditions, such as breast cancer (123) 
and low-back pain (124). In a meta-analysis, the authors concluded that 
meditative movements, such as yoga, increase QoL in adults with various 
conditions, such as breast cancer, schizophrenia, low-back pain, heart-failure 
and diabetes mellitus (125).  
MediYoga  
MediYoga is a therapeutic form of yoga derived from Kundaliniyoga. This form 
of yoga has been evaluated by the MediYoga Institute, Stockholm, Sweden 
(126). The MediYoga program has been evaluated for use with different 
conditions and diseases, including heart diseases. The program for heart 
diseases is designed to stretch the musculature in the chest to achieve better 
breathing and relax the body. MediYoga is based on a deep breathing 
technique and consists of slow movements as well as meditation, Supplement I-
II. MediYoga is commonly performed lying or sitting on a blanket, but can also 
be performed sitting on a chair, Figure II. MediYoga may be performed by all 
ages (126). It is considered to be cost-effective and increase QoL more than 
standard treatment (physiotherapy) in patients with low-back pain (127). 
Patients have also reported that MediYoga has provided them with a tool to 
handle their stress (128).  
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Figure II. Movements performed in the MediYoga program by permission of photograph 
Anton Svedberg
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AIM 
 
OVERALL AIM 
The overall aim of this thesis was to study the effects of MediYoga among 
patients with PAF. In addition, to describe perceptions and experiences of 
MediYoga as well as to evaluate gender differences. 
 
SPECIFIC AIM 
I. To analyse the effects of yoga on HRQoL (SF-36 and EQ Visual Analog         
Scale), blood pressure and heart rate among patients with PAF. 
II. To evaluate the effects of MediYoga in respect of HRQoL (SF-36 and 
ASTA), blood pressure, heart rate as well as NT-proBNP among patients with 
symptomatic PAF, compared to standard therapy or relaxation. 
III. To describe perceptions and experiences of MediYoga among patients with 
symptomatic PAF. 
IV. To evaluate gender differences, after performing MediYoga, in HRQoL, 
blood pressure and heart rate among patients with PAF. Furthermore, to 
evaluate differences, in HRQoL, blood pressure and heart rate with-in the male 
and female group.  
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DESIGN AND METHODS 
 
This thesis consists of four papers with quantitative designs (Papers I, II and IV) and 
a qualitative design (Paper III). An overview of the four sub-studies is given in Table 
II. Also, a description of Paper I and II is provided to clarify similarities and 
differences in inclusion- and exlusion criterions as well as assessments, Table III. 
 
Table II. Overview of the four papers in this thesis 
 
 Paper I Paper II Paper III Paper IV 
Design  Randomized 
controlled design - a 
pilot study 
Three-armed, 
randomized controlled 
design with stratification 
in gender 
Semi-structured 
interviews design 
Comparative 
design  
Sample 
and study 
group 
80 patients were 
randomized to yoga 
(n=40) or control 
group (n=40) 
132 patients were 
randomized to yoga 
(n=44), relaxation (n=44) 
or control group (n=44) 
12 participants 
whom performed 
MediYoga from 
Paper II were 
included  
37 females and 
34 males were 
included from 
yoga groups 
Papers I and II 
 
Data 
collection 
HRQoL questionnaire 
(SF-36, EQ-5D VAS 
analogue scale), 
blood pressure, heart 
rate, demographic 
data, data from 
medical records, 
medications, amount 
of yoga sessions at 
home 
HRQoL questionnaires 
(SF-36, ASTA), blood 
pressure, heart rate, NT-
proBNP, demographic 
data, data from medical 
records, medications, 
document of 
symptomatic 
palpitations, amount of 
yoga sessions at home 
Individual 
interviews 
HRQoL 
questionnaire 
(SF-36), blood 
pressure, heart 
rate, 
demographic 
data 
 
 
 
 
 
 
 
 
 
 13 
 
Table III. Description of Paper I and Paper II in inclusion- and exlusion criterions as well  
as assessments 
Inclusion criterion Exclusion criterion Paper I  
Pilot study 
Yoga/Control 
Paper II 
Yoga/Relaxation/ 
Control 
Paroxysmal atrial 
fibrillation 
 X  
Symptomatic 
paroxysmal atrial 
fibrillation 
  X 
 Diabetes mellitus  X 
 Untreated hyperthyroidism  X 
 Multiple concurrent 
medical conditions 
X X 
 Cognitive dysfunction X X 
 Difficulties to 
understanding the 
Swedish language 
X X 
Assessment    
SF-36  X X 
EQ VAS  X  
ASTA   X 
Blood pressure  X X 
Heart rate  X X 
NT-proBNP   X 
STUDY GROUPS  
The study groups which were used in Paper I-IV are described in Table IV 
        Table IV. Descriptions of study groups used in Paper I-IV 
 
 
 
 
 
 
 
          
Papers I-IV 
The MediYoga group performed yoga an hour a week for 12 weeks at the hospital. 
The MediYoga group received a CD-record with the yoga program and was 
encouraged to perform MediYoga at home. The program consisted of light 
movements, meditation and relaxation and could be performed sitting in a chair or on 
the floor, as described in Supplement I-II. 
The MediYoga group also received standard medical treatment such as rhythm and 
rate regulating drugs and in a few cases cardioversion. 
Papers I-II 
The control group only received standard treatment. 
 Paper I Paper II Paper III Paper IV 
MediYoga X X X X 
Control X X   
Relaxation  X   
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Paper II 
The relaxation group was listened to relaxing music, in group sessions, for half an 
hour, once a week for 12 weeks at the hospital. The relaxing music in this study has 
been used in stress relief programs (98, 129). 
The relaxation group also received standard treatment. 
PARTICIPANTS AND SETTING 
All studies were conducted at Danderyd’s University Hospital, Stockholm, Sweden. 
Paper I 
The study was conducted between 2009 and 2012. Eighty–eight patients with PAF 
were identified from medical records and recommendations from the staff at the 
arrhythmia department’s out-patient clinic. They were asked by telephone to 
participate. Eighty patients fulfilled the inclusion criteria and agreed to participate in 
the study, Figure III. An informed consent was conducted before the randomization. 
The inclusion criterion was a diagnosis of PAF, either early or new, and should have 
been on medical treatment for PAF for at least three months.  
Patients with multiple, concurrent medical conditions (i.e. cancer, heart failure and 
renal failure with symptoms), cognitive dysfunction or with difficulties in 
understanding the Swedish language were excluded.  
The patients were randomly assigned in blocks of five, by a permuted block 
randomization, inspired by Polit and Beck (130).  
 
 
Figure III. Flow-chart and inclusion paper I 
Patients from 
Arrhythmia Unit 80 
Randomization at 
Visit I (baseline)
Yoga group n=40 
Analysed
n=33
Drop outs n=7
Control group n=40 
Analysed
n=36
Drop outs n=4
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Paper II 
This study was conducted between 2014 and 2017 and the participants were 
randomly selected, with stratification for gender. The patients were identified from an 
arrhythmia unit’s medical records and/or referrals from one other arrhythmia 
department. The patients were contacted by telephone by the principal author (PA) 
and were informed verbally about the study. If patients were interested in 
participating, the PA sent information about the study and an invitation to the first 
visit. The inclusion criterion was a diagnosis of symptomatic PAF, defined as at least 
one episode of ECG verified AF during the past six months. The patients had been 
receiving pharmacological treatment for at least the past three months and had a 
recent, within the past year, diagnosis of PAF. 
Patients with diabetes mellitus and with an untreated hyperthyroidism were 
excluded. Patients with difficulties understanding the Swedish language, those with 
multiple concurrent medical conditions (i.e. advanced cancer, heart failure and renal 
failure) or/and cognitive dysfunction were also excluded. 
Of 1,532 screened patients, 152 fulfilled the inclusion criteria and 132 patients 
agreed to participate in the study, Figure IV. The high number of patients who could 
not participate was explained by incorrect diagnoses (persistent AF instead of PAF), 
diabetes mellitus, not adjusted TSH values and not symptomatic PAF. 
An informed consent was conducted before collecting any assessments as well as 
performing the randomization. At the end of the baseline visit the participants were 
randomized to blocks of six (131).  
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Figure IV. Inclusion flow-chart and drop-outs, paper II
1532 patients were screened at the 
Arrythmia Centre and referrals from 
one other arrhythmia department 
  
1380 patients did not fulfil 
inclusion criteria, e.g 
diabetes mellitus, 
untreated 
hyperthyroidism, non-
symptomatic PAF, 
diagnosis of persistent 
PAF  
  
152 patients were eligable for inclusion 
  
132 patients agreed to participate 
  
44 patients randomized to 
MY group 
  
44 patients randomized to 
relaxation group 
  
44 patients randomized to 
control group 
  
6 drop-outs 
  
15 drop-outs 
  
3 drop-outs 
  
38 patients were included in 
the analysis 
  
29 patients were included in 
the analysis  
  
41 patients were included in 
the analysis  
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Paper III 
The participants were enrolled from Paper II, from February 2015 to May 2017, and 
were asked at the first visit (baseline) to participate in the study (Paper III). 
Meanwhile the study (Paper II) was in progress; the participants were selected 
consecutively at the second visit and asked by the PA to participate in the interview 
study. The selection of participants to the interview study was carried out according 
to the principal author’s time frame, while including participants in Paper II. The 
subsequent interview was scheduled to suit the participants. Fifteen patients were 
approached, all agreed to participate in the interview study, but only twelve patients 
were included. 
 Paper IV 
Females and males were included from Paper I (females n=17, males n=16) and 
Paper II (females n=20, males n=18). Flow-chart is described in Figure V. 
 
 
Figure V. Inclusion flow-chart, paper IV 
 
 
 
 
 
 
Inclusion from 
Arrhythmia Unit 
First study 80 
patients randomized
Yoga group
n=40
Analysed n=33
Females n=17 
included
Males n=16 included
Control group n=40
Second study 132 
patients randomized
Yoga group 
n= 44
Analysed n=38
Females n=20 
included
Females n=37 and 
Males n=34 
included
Males n=18 included
Control group n=44
Relaxation group 
n=44
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DATA COLLECTION 
Paper I 
All participants made two visits; baseline and end of study (with a visit-window of ≤ 2 
weeks). At both visits the participants met the PA to assess HRQoL and 
hemodynamic parameters. The two visits were held in the morning in the same room 
at the hospital for both groups. The participants completed the HRQoL 
questionnaires, at the baseline visit, before randomization to their respective groups. 
Treatment history was collected from medical records at baseline and at the end of 
the study. The participants informed the PA, at end of the study, of how many yoga 
sessions they had conducted at home. 
 
Paper II 
 
The participants attended two appointments (to the PA), at baseline and after 12 
weeks (visit window ≤ 2 weeks).  
Data collection (i.e. demographics [such as sleeping habits, alcohol use, 
employment, exercise habits and life events], HRQoL questionnaires, hemodynamic, 
and venous blood samples) took place at both visits. Data were collected at the 
baseline visit before randomization. Medication information was collected from the 
medical records and confirmed by the participants at baseline and at the end of the 
study. The participants were encouraged to document their symptomatic episodes of 
palpitations during the study. The same environment was used for all visits and there 
were no changes over time. The participants informed the PA, at the end of the 
study, about how many yoga sessions they had performed at home. 
Paper III 
 
Data were obtained from semi-structured interviews that were conducted face to 
face. All three authors performed the interviews individually. The interviews were all 
carried out in the same venue at the hospital. To ensure consistency (132), a written 
semi-structured interview guide, with open and follow-up questions, was constructed 
and used, Supplement III. Two participants were asked to participate in pilot-
interviews. The data from these were evaluated by the authors and the questions 
were revised slightly to elicit responses more closely related to the aim of the study. 
The pilot-interviews were included in the study. The authors perceived a repeated 
pattern in the analysis after ten interviews. To ensure a sufficiently large sample 
(133), two more patients were included. 
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Paper IV 
 
Data were obtained from Paper I and Paper II, respondents from the MediYoga 
groups. In this, we included assessments such as HRQoL and hemodynamic 
parameters, which were measured at baseline and at the end of study. 
 
ASSESSMENTS 
  
Health-related questionnaires 
 
EQ-5D Visual Analog Scale  
In Paper I we used the EQ-5D Visual Analog Scale (EQ VAS) which is a part of EQ-
5D and is a standardized, validated and reliable scale (18, 19). EQ-5D consists of 
two parts: a descriptive component and a Visual Analog Scale (VAS). In this study, 
we used only the EQ VAS. This scale measures self-rated health status and consists 
of a scale between 0-100, where 100 is the best possible state of QoL. The 
instruction was, ”We would like you to use this scale to indicate how good or bad 
your health is, right now”.  
EQ-5D is a well-known and widely used assessment instrument. It has been used 
worldwide in various AF contexts (69, 70, 134, 135). 
Short-Form Health Survey (SF-36) 
In Papers I-II, IV we used the Short-Form Health Survey (SF-36), which is a generic, 
validated and reliable HRQoL questionnaire comprising 36 items (136, 137) that 
measure the individual’s physical and mental health. The questions are answered by 
choosing five or six possible responses: very poor, poor, little poor, little good, good 
or very good. The questions are divided into eight subscales; physical functioning 
(PF), role-physical; because of physical health problems (RP), bodily pain (BP), and 
general health (GH), which also generate the dimension Physical components 
summary (PCS). Vitality is addressed by: energy/fatigue (VT), social functioning 
(SF), role-emotional; role limitations because of emotional problems (RE), mental 
health; psychological distress and psychological well-being (MH), which also 
generate the dimension Mental components summary (MCS). The items, sub-scales 
and dimensions are scored, summarized and analysed with syntax into scores of 0-
100, where 100 is the best state of HRQoL.  
SF-36 is a well-known assessment instrument, takes 10-15 minutes to answer and 
has been used worldwide in various AF contexts (35, 138-141).  
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Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia (ASTA) 
In Paper II we used ASTA. This is a disease-specific validated questionnaire which 
is divided into three parts (142, 143). Part I evaluates the latest episode 
of arrhythmia and current medication. Part II assesses symptom burden, and 
includes a 9-item symptom scale (ASTA symptom scale) with 4 possible responses. 
There are also questions regarding the frequency and the duration of an arrhythmia 
episode, experience of near syncope, syncope, and palpitations in connection with 
arrhythmia. Part III assesses HRQoL, using 13-items (ASTA HRQoL scale), with the 
same 4 responses as for the symptom scale. The ASTA HRQoL scale is divided 
further into a physical and a mental subscale. The values range from 0 to 100 where 
higher scores reflect a higher symptom burden and a worse effect on HRQoL due to 
the arrhythmia. This questionnaire has been validated with SF-36 (70, 142, 143). 
 
Blood pressure, heart rate and NT-proBNP 
Papers I-II, IV 
Blood pressure and HR were measured, after a resting period of five minutes (144), 
with Omron HEM-711DLXCAN. 
 
Paper II 
 
NT-proBNP were analysed with Roche h232 (145). 
 
Demographic data 
 
Measurements of height, weight and waist were taken by the PA. The PA also 
collected demographic information from the participants, e.g. marital status, income, 
exercise activity, alcohol use, working and sleeping habits. 
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       DATA ANALYSIS 
      The various methods of analysis used in this thesis are described in Table V. 
        Table V. Methods of analysis  
Data analysis Paper I Paper II Paper III Paper IV 
Chi-square test  X X  X 
Student's t-test X X  X 
Mann Whitney U test X    
The Wilcoxon Signed Ranks test X    
Analysis of covariance (ANCOVA) X X   
One-way ANOVA  X   
Sidak as post-hoc test  X   
Linear regression analysis    X 
Content analysis   X  
Categorical variables are presented as median (range) or percent, and      
continuous variables are presented as mean (standard deviation, [SD]). A chi-
square test was performed for proportions, and analysis of covariance 
(ANCOVA) was used if a statistically significant relationship was demonstrated 
between the groups in demographic data.  
As Paper I is a pilot study, a power calculation was not made, although we 
looked at earlier yoga intervention studies to obtain an indication as to a 
satisfactory sample size (146). 
Paper II The power calculation was based on data from the pilot study. A 
significance level of p < 0.05 was chosen, within groups, with an eight-point 
difference for all the scales of SF-36 (147). To detect an eight-point mean 
difference in the scales of SF-36 between the groups, using an alpha of 0.016 
and a power of 0.80, 44 patients were required in each group, including 20 
percent of drop-outs. 
Paper IV A linear regression analysis within PCS (SF-36), MCS (SF-36) as well 
as gender, was performed in order to ascertain whether the sample from the two 
studies was of sufficient size. There was no significant interaction between the 
two groups. 
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In Paper I the variables have been processed statistically using the data analysis 
program, SPSS version 12. In Papers II and IV we used the data analysis program 
IBM SPSS statistics version 24 (IBM SPSS Statistics, IBM Corporation, Armonk, 
New York). 
Paper III The interviews were analysed using qualitative content analysis, with an 
inductive method, in a manifest approach (148). Content analysis is a method of 
systematically analysing written or verbal communication (149). A manual method 
was used to organize the data (150). The interviews were audio recorded and 
transcribed verbatim by the PA. To verify that the transcription was correct, the 
recorded interviews were compared with the text. After several discussions between 
the authors, the meaning units with the same pattern and which corresponded with 
the aim of the study, were identified and labelled by codes. Subsequently, sub-
categories and categories were identified. The duration of the interviews was 17- 32 
minutes and they were conducted not more than four weeks after the final 
intervention of the previous study. 
One contribution of a qualitative method is to capture stories to understand people’s 
perspectives and experiences where the story, ‘well-told’ and well-documented, 
opens a window into the world of the studied cases. Content analysis is one of many 
methods used to analyse text from interviews and can be conducted using an 
inductive and deductive approach. An inductive approach has a known phenomenon 
where the researcher includes data and subsequently forms hypotheses and 
theories. A deductive approach entails testing already formulated hypotheses and 
theories. In this study, we used an inductive approach with the purpose of exploring 
an already formulated aim without a theory or hypothesis. In this context, we wanted 
to examine patients’ experiences and perceptions. In a manifest approach, as in this 
paper, texts are interpreted less than in a latent approach. The challenge is to 
ensure the credibility of the analysis of categories and themes so as to attain a 
balance in the interpretations (149, 151).   
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ETHICAL CONSIDERATIONS 
 
All the papers conform to the principles outlined in the Declaration of Helsinki (152) 
and were approved by the Ethics Committee of Stockholm, Sweden ( Paper I DNR 
2008/1983-31/2 and Papers II-IV DNR 2013/953-31/4). 
All participants received verbal and written information about the study. All 
participants provided written informed consent at baseline and were informed that 
they were free to withdraw their participation at any time and that the non-
participation would not influence the participants´ future health care.  
A counsellor was attached to the study to offer help to any patients experiencing 
emotional reactions arising from answering the questionnaires and being 
interviewed. 
In Paper III the participants were informed that it was possible to discontinue the 
interview without given a reason and that the non-participation would not influence 
the participants´ future health care.  
Ethical considerations round the MediYoga program were conducted before the 
studies started. There were no reports that MediYoga caused any adverse events, 
although, a soreness in the muscles were noticed and described from the 
participants. The participants were also informed that blood sample may cause some 
pain and in worse case a bruise and an infection. There was no report from the 
patients that the blood sample had caused any events. 
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RESULTS 
 
PAPER I  
In the MediYoga group, 33 patients completed the intervention. Seven patients 
(17.5%) – four men (10%) and three women (7.5%) – dropped out before the 
completion of the study period. In the control group, 36 patients completed the study 
period; four male patients (10%) ceased to participate. Baseline characteristics are 
shown in Table VI.  
On average, the participants in the MediYoga group performed ten yoga sessions 
(range 8-12) at the hospital. At-home yoga was conducted a median of 2 (range 1-4) 
sessions per week.  
 
Table VI. Baseline Characteristics  
 
 
MediYoga 
n=33 
Control 
n=36 
Age  64±7 63±8 
Female gender 16 (48) 25 (71) 
Hypertension 14 (42) 19 (52) 
Diabetes mellitus 0 (0) 3 (8) 
Stroke/Transitory Ischemic Attack 5 (15) 0 (0) 
Ischemic Heart disease 0 (0) 1(3) 
Heart failure 0 (0) 1(3) 
Medications   
Beta blockers 27 (82) 30 (83) 
Calcium channel blockers 10 (30) 11(31) 
Antiarrhythmic medications 13 (39) 21 (58) 
ACE (Angiotensin enzyme inhibitor) 9 (27) 15 (42) 
Statins 9 (27) 14 (39) 
Warfarin 18 (55) 20 (56) 
Aspirin 10 (30) 12 (33) 
Values are n (%) and mean ±SD.  
 
Health-related quality of life 
At baseline, the MediYoga group reported a significantly lower QoL on the EQ VAS. 
After 12 weeks, the patients’ EQ VAS scores had increased significantly (p <0.001) 
in the MediYoga group, whereas the control group reported no change (p=0.622). 
The same pattern was seen in SF-36 MCS, with significant improvement in the 
MediYoga group (p <0.001); but lacking in the control group (p=0.782). There was a 
significant difference in MCS at baseline between the groups (p=0.001) as well as an 
increase for the MediYoga group at the end of study (p=0.016), Table VII. 
 
 
 
 
 25 
 
Table VII. Health-Related Quality of Life 
Type of 
score 
Yoga 
 
Yoga 
  
Control  
 
Control 
  
Between 
groups 
Between  
Groups 
Within  
Yoga  
Within 
Control  
Baseline  Follow-up Baseline Follow-up     Baseline Follow-up Follow-up Follow-up 
n= 33 n=33 n= 36 n=36 p-value p-value 
 
p-value  
 
p-value 
EQ-5D 
VAS-scale 
70.0  
(20.0–95.0) 
80.0  
(50.0–100.0) 
80.0 
 (30.0-100.0) 
80.0  
(30.0-95.0) 
0.025* 0.598 0.001* 0.622 
 
SF-36 MCS 42.1  
(17.6-53.5) 
50.6  
(24.0-55.2) 
53.0  
(14.7-56.0) 
52.7  
(24.5-57.1) 
0.001* 0.016* 0.001* 0.782 
 
SF-36 PCS 46.7  
(28.8-60.6) 
50.2 
 (27.6-59.1) 
52.2 
(25.2-65.0) 
49.0  
(29.1-61.6) 
0.172 0.837 0.091 0.321 
 
Values are median (interquartile range). * Statistically significant with a p-value < 0.05. SF-36; Short-Form Health Survey. 
Dimensions of SF-36; PCS; Physical Components Summary, MCS; Mental Components Summary. 
 
Hemodynamic Assessments  
After 12 weeks of MediYoga, systolic (p=0.033) and diastolic (p<0.001) blood 
pressure as well as heart rate (p=0.024) were significantly lower in the MediYoga 
group compared to the control group. There was also a reduction within the 
MediYoga group in diastolic blood pressure (p<0.001) and within the control group in 
heart rate (p=0.05).Table VIII. 
Table VIII. Hemodynamic assessments 
 
 
 
MediYoga 
Baseline  
n= 33 
 
 
Control  
Baseline 
n= 36 
  
 
MediYoga 
Follow-up  
n=33 
 
Control 
Follow-up 
n=36 
  
 
 
Between 
Groups 
Baseline 
p-value 
Between  
Groups 
Follow-up 
p- value 
 
 
Within 
MediYoga  
Follow-up 
p- value 
 
 
Within  
Control 
Follow-up 
p- value 
Heart rate/ 
minute 
 
64±13 
 
65±14 
 
61±13 
 
70±19 
 
 
0.740 0.024* 
 
 
0.183 
 
0.05* 
 
SBP mm-Hg 
 
137±16 
 
138±18 
 
132±17 
 
141±17 
 
0.727 0.033* 
 
0.69 0.410 
DBP mm-Hg 
 
84±9 
 
84±12 
 
77±10 
 
86±12 
 
0.735 0.001* 
 
<0.001* 0.250 
* Statistically significant with a p- value < 0.05. SBP: Systolic Blood pressure; DBP: Diastolic Blood Pressure. 
PAPER II 
There were six drop-outs in the MediYoga group (16%), four men and two women, 
fifteen drop-outs (34%), eight women and seven men in the relaxation group and 
four drop-outs (9%), three men and one woman in the control group, Figure IV. The 
MediYoga group performed yoga sessions at home, with a median of 12 sessions (0 
to 60) during 12 weeks. 
Clinical characteristics of drop-outs are shown in Table IX. 
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Table IX. Clinical Characteristics drop-outs 
 MediYoga 
n=6 
Control 
n=3 
Relaxation 
n=15 
Female gender 2 (33) 1 (33) 8 (53) 
Age 
Age median 
63±6 
62 (56-73) 
67±11 
66 (56-78) 
66±10 
70 (44-77) 
BMI 
BMI median 
29±7 
28 (23-43) 
30±6 
29 (25-37) 
25±4 
25 (21-34) 
Good sleep 2 (33) 2 (67) 9 (33) 
Employment 2 (33) 2 (67) 5 (33) 
High intensive training 1 (17) 1 (33) 0 
Life events 3 2 4 
Alcohol glasses/week 7±2 5±2 4±2 
Hypertension 4 2 6 
Stroke 1 1 4 
MI - - - 
Heart failure - - - 
Sleep apnea - - - 
Values are mean (SD), n (%). MI; myocardial infarction. BMI; body mass index. 
There were more participants in the MediYoga group with hypertension compared to 
the control and relaxation group. When adjusted for hypertension in SF-36 
(subscales and domains), ASTA (all three parts), BP, HR and NT-Pro-BNP there 
was no difference between the groups. There were no differences between the 
groups when adjusted for outliers at the end of study, with respect to documented 
episodes of AF (yoga 13.6±8, control 9±8, relaxation 7.6±6). The attendance rate at 
the MediYoga group showed a median nine (7 to 11) and for the relaxation group 
median six (3 to 12). There were no adverse events reported by the MediYoga- or 
relaxation groups during the study. Clinical characteristics are shown in Table X.  
Table X. Clinical Characteristics  
 MediYoga 
n= 38 
Control 
n=41 
Relaxation 
n=29 
Age  65 ±9 63±10 64±15 
Female gender 20 (53) 21 (51) 14 (48) 
BMI (kg/m²) 26.5±3.4 25.4±6.1 28.2±12.1 
Employment 16 (42) 20 (49)  20 (69) 
Good sleep 34 (89) 34 (83)  20 (69)  
High intensive exercise 8 (21)  7 (17) 7 (24) 
Life events 8 (21)  15 (37)  10 (35)  
Alcohol glasses/week 3.1 (0 - 15) 3.1 (0 - 14) 3.8 (0 - 18) 
Medical history    
Hypertension 22 (58)* 11 (27)  6 (21) 
Stroke 1 (3)  - - 
MI - 2 (5) - 
Heart failure - - 1 (3) 
Sleep apnoea 4 (11) 5 (12)  4 (14)  
CHA2DSs VASc 2 (0 - 4) 1 (0 - 4) 1 (0 - 4) 
Medications    
Beta blockers 25 (66) 28 (68) 20 (69) 
Antiarrhythmics drugs 16 (42) 19 (46) 8 (28) 
Calcium antagonists 7 (18) 4 (10) 3 (10) 
DOAC (direct oral 
anticoagulants) 
18 (47) 16 (39) 14 (48) 
Warfarin 11 (29) 10 (24) 1(3) 
ASA (aspirin) 2 (5) 2 (5) 2 (7) 
Values are n (%) and mean ±SD. CHA2DSs VASc is described in median (range). 
* Statistically significant with a p-value < 0.05 
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Health-related quality of life 
No differences were observed between the groups regarding SF-36, subscales and 
domains, at the end of the study. However, there was a significant improvement 
with-in the MediYoga group in the subscales bodily pain (BP), p=0.019, general 
health, (GH), p=0.037, social functioning (SF), p=0.029, mental health (MH), 
p=0.030, and mental component summary (MCS), p=0.019. Over time, there were 
no differences within relaxation- or control groups regarding subscales and domains 
of SF-36, Table XI. Moreover, there were no differences in ASTA, all three parts, 
between the groups at the end of the study. There was a significant improvement in 
HRQoL, ASTA, subscale MH (p=0.035) with-in the control group but no differences 
were seen within the yoga- or relaxation groups, Table XI. 
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Table XI. Health-related quality of life questionnaires 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean and SD.* Statistically significant with a p-value < 0.05. MY; MediYoga. SF-36; Short form health survey. Sub-scales of SF-36; PF; physical functioning, RP; role-physical, BP; bodily pain,  
GH; general health, VT; vitality, SF; social functioning, RE; role-emotional, MH; mental health. Dimensions of SF-36; PCS; Physical Components Summary, MCS; aental Components 
Summary. ASTA; Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia 
 
 
 MediYoga 
 n=38 
 
 
 
Baseline 
 MediYoga 
 n=38 
 
 
 
End of study 
Control 
n=41 
 
 
 
Baseline 
Control 
n=41 
 
 
 
End of study 
Relaxation 
n=29 
 
 
 
Baseline 
Relaxation 
n=29 
 
 
 
End of study  
Between 
groups 
MY/Control/ 
Relaxation 
End of study 
p-value 
Within 
MediYoga 
End of study  
 
 
p-value 
Within Control 
End of study 
  
 
 
p-value 
Within Relaxation 
End of study  
 
 
 
p-value 
Typ of score 
SF-36 
          
PF 83±18 86±14 87±13 85±14 84±14 82±12 0.559 0.485 0.565 0.564 
RP 61±43 68±40 72±37 58±43 59±42 47±44 0.234 0.485 0.100 0.316 
BP 70±27 83±19 80±24 76±23 75±24 69±24 0.041 0.019* 0.448 0.389 
GH 61±18 70±17 65±22 65±21 62±19 61±20 0.240 0.037* 0.924 0.389 
VT 53±18 61±17 55±22 57±16 56±17 53±18 0.244 0.076 0.553 0.570 
SF 75±28 88±18 81±23 83±19 75±28 75±30 0.295 0.029* 0.631 0.962 
RE 60±43 77±35 74±36 66±40 58±39 56±47 0.131 0.058 0.372 0.918 
MH 64±16 72±16 67±16 67±13 65±16 66±16 0.335 0.030* 0.905 0.836 
PCS 48±9 50±8 50±9 48±8 49±8 46±8 0.176 0.337 0.266 0.156 
MCS 40±11 46±9 43±12 43±9 40±12 41±14 0.266 0.019* 0.266 0.849 
Typ of score 
ASTA 
          
Symptom 
scale 
26 ±15 27±18 33±18 30±16 34±16 30±17 0.093 0.556 0.051 0.052 
HRQoL scale 22±14 21±17 29±21 25±18 23±20 29±25 0.363 0.440 0.067 0.425 
HRQoL 
subscale 
physical 
21±16 21±19 30±23 26±21 28±24 28±26 0.330 0.951 0.152 0.941 
HRQoL 
subscale 
mental 
23±16 20±17 
 
29±20 23±16 32±25 
 
29±25 0.606 0.096  0.035* 
 
0.107 
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Blood Pressure 
Between the MediYoga group (134±18 to 127±13) the control group (126±17 to 
127±15), p = 0.041, and the relaxation group (131±17 to 125±12) no differences 
were observed in systolic blood pressure (SBP). There was a significant difference 
within the MediYoga group (p=0.008) and within the relaxation group (p= 0.025), 
over time. Moreover, diastolic blood pressure (DBP) decreased significantly in the 
MediYoga group (79±9 to 74 ±9) compared to the control group (76±9 to 79±8), p = 
0.005, but no difference was seen in comparison to the relaxation group (76±9 to 
77±8), Figure VIa and VIb. There was also a significant difference in DBP within the 
MediYoga group (p=0.002). 
 
Figure VI a. Changes in systolic blood pressure with-in the groups over time. Mean differences 
in systolic blood pressure within MediYoga (MY), relaxation and control group after 12 weeks (SD; 
standard deviation). 
 
Figure VI b. Changes in diastolic blood pressure with-in groups over time Mean differences in 
diastolic blood pressure within MediYoga (MY), relaxation and control group after 12 weeks (SD; 
standard deviation). 
Heart rate and NT-proBNP 
Regarding HR there were no differences between the groups; MediYoga/control 
(p=0.999), MediYoga/relaxation (p=0.993) and control/relaxation (p=0.976) or NT-
proBNP between the groups; MediYoga/control (p=0.860), MediYoga/relaxation 
(p=0.364) and control/relaxation (p=0.777) at the end of study. There were 
significant differences in NT-proBNP between the MediYoga and relaxation groups 
at baseline (p=0.015) and between the control and /relaxation groups (p=0.012). 
CONTROL 0,54
(13,2)
RELAXATION 
-5,83 (13,1)
MY  -7,11 (15,7 
-8 -7 -6 -5 -4 -3 -2 -1 0 1
CONTROL  1,44
(9,1)
RELAXATION  
-5,83 (9,0)
MY -5,61 (10,1)
-7 -6 -5 -4 -3 -2 -1 0 1 2
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There were no differences with-in any of the groups in HR and NT-proBNP, Figure 
VII and VIII. 
 
HR; heart rate. Mean, SD. 
Figure VII. Heart rate with-in groups over time. Mean in heart rate between MediYoga,  
relaxation and control group after 12 weeks. 
 
 
NT-proBNP; N-terminal Prohormone Brain Natriuetic Peptide, ng/ml; nanogram per millimetre. 
Mean, SD. 
Figure VIII. NT-proBNP with-in groups over time. Mean in NT-proBNP between MediYoga, 
relaxation and control group after 12 weeks.  
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PAPER III 
The participants in this study were those performing MediYoga in Paper II and 
comprise seven men and five women with an age range of 49 to 82 years (median; 
63.5 years). Characteristics are shown in Table XII.  
 
Table XII. Characteristics of participants 
Gender Age Hypertension Stroke MI* CH2DS2-
VASc 
Score 
(0-10) 
Number of 
yoga 
sessions at 
hospital 
Number of 
yoga 
sessions at 
home 
Male 50 - - - 0 7 35 
Female 66 - - - 2 10 48 
Male 49 - - - 0 10 24 
Female 62 X - - 2 9 2 
Male 68 - - - 1 10 0 
Male 77 X - - 2 9 10 
Female 71 X - - 3 7 60 
Male 61 - - - 0 9 36 
Female 82 X - - 3 11 0 
Male 52 X - - 1 9 12 
Male 65 X - - 0 9 0 
Female 54 - - - 2 10 12 
*MI=Myocardial Infarction. 
Three categories were identified that describe the patients´ perceptions and 
experiences of MediYoga: ̔A time for a sense of existence and presence`, ̔ A way 
of gaining well-being and increased consciousness ̓ and ̔ Access to a tool to 
gain willpower and relieve symptoms ̓. 
The category  ̔ A time for a sense of existence and presence` was described by 
patients as increased thoughtfulness and experiences of gaining access to their 
inner self. Moreover, the patients reported feelings of inner-peace, inspiration as well 
as expressions of transferring themselves to a deeper level in their minds, after 
taking part in yoga sessions. Patients also described a sense of presence, and, in 
this context, a feeling of being more profound and being in the moment. Some 
sensations were reported as being difficult to explain but were referred to as a higher 
level of presence and a state in which they wished to remain. 
“….then I was in my own world ...” then you don't worry about anything else really, 
you just are…//…you didn´t want to let go of the feeling…//…more unaffected by the 
surroundings….and you were more present….// 
The category, ̔ A way of gaining well-being and increased consciousness  ̓was 
described in two sub-categories:  ̔ experience of an increased well-being ̓ and ̔ 
increased awareness of the connection between physical and mental functions .̓ 
Patients described feelings of enhanced well-being and relaxation after MediYoga. 
They described it as a feeling of comfort, with components of mental and physical 
well-being. The patients also perceived that they achieved an enhanced 
connection with their breathing and anatomy. They reported being able to improve 
their bodily functions and described an increased consciousness as to how to 
affect their body. 
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“//…..I felt a total relaxation in body and mind….//….You feel more alert when you 
come out of the session ... you feel peaceful and you feel it ... lighter in body…..//” 
“//…The physical part greatly affects the mental component……. Increased 
awareness of the importance of doing this and that I can influence it. ... // ” 
The category, ̔ Access to a tool to gain willpower and relieve symptoms ̓ 
describes two subcategories: ̔ an accessible tool ̓ and  ̔reduction of bodily 
symptoms ̓. The patients experienced that they had obtained access to a tool for 
handling emotions, such as fear and anxiety, that they struggled with between and, 
also during, their episodes of atrial fibrillation. Patients also reported a reduced 
duration and frequency of heart symptoms. They experienced a substantial effect 
regarding symptoms of palpitations and were able to revoke the symptom of 
irregular heartbeat. 
“ I still have my irregular heartbeats then, but I feel I handle it better, I'm not as afraid 
...//...I do not have them as often and I think I can handle myself and them better.” 
“I felt clearly that there’s a connection, at least indirectly, that you can influence how 
stressed you are through yoga and that it can affect the atrial fibrillation and 
frequency ... I have actually been free of symptoms in principle the past three 
months.” 
PAPER IV 
Thirty-three completed the intervention and were then analysed (assessments) in 
Paper I, 17 women (52%) and 16 men (48%). In Paper II, the number of patients 
was 38, women 20 (53%) and men 18 (47%), respectively. The average age for 
women was 66±8 and for men 62±9. Women had more hypertension, 23 (62 %), 
than men, 14 (41%), but no significant difference was observed. Clinical 
characteristics are shown in Table XIII. 
 
Table XIII. Clinical characteristics 
 
Values are mean (SD), n (%). MI; myocardial infarction. ACE; angiotensin-converting-enzyme.  
 
Women 
n=37 
Men 
n=34 
Age 66±8 62±9 
Hypertension 23 (62) 14 (41) 
Heart Failure 0 (0) 0 (0) 
MI 0 (0) 0 (0) 
Stroke 1 (3) 2 (6) 
Beta blockers 27 (73) 23 (68) 
Calcium antagonists 9 (24) 8 (24) 
Antiarrhythmics drugs 14 (38) 13 (38) 
Warfarin 17 (46) 12 (35) 
DOAC (direct oral anticoagulants) 1 (3) 8 (24) 
ASA (aspirin) 5 (14) 8 (24) 
Digoxin 1 (3) 1 (3) 
ACE inhibitor 12 (32) 10 (29) 
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Health-related quality of life 
The results showed no differences between the women’s group (WG) and the men’s 
group (MG) at baseline or at the end of study. However, with-in the WG 
improvements were observed in subscales VT (p=0.008), SF (p=0.040), MH 
(p=0.006) and the domain MCS (p=0.026). Also, there were improvements with-in 
the MG in subscales RP (p=0.045), BP (p=0.007), GH (p=0.002), VT (p=0.015), SF 
(p=0.002), RE (p=0.013) and the domain MCS (p=0.009). No improvement was seen 
in PCS in either of the groups, Table XIV. 
 
Table XIV. Changes in SF-36 over time 
Type of 
score 
SF-36 
 
  
 
WG 
n=37  
Baseline 
 
WG 
n=37  
End of study 
 
MG 
n=34  
Baseline 
 
MG  
n=34  
End of study 
 
Within 
WG 
End of 
study 
p-value 
Within 
MG 
End of 
study 
p-value 
Between  
Groups 
End of 
study 
p-value 
 
PF   80±20 80±14 82±17 88±15 0.796 0.066 0.252 
RP   60±42 65±41 59±42 75±34 0.608 0.045* 0.347 
BP   74±26 78±23 67±28 82±23 0.349 0.007* 0.136 
GH   61±22 67±18 59±20 71±21 0.094 0.002* 0.254 
VT   51±19 61±16 55±15 65±17 0.008* 0.015* 0.978 
SF   71±29 82±20 71±26 87±20 0.040* 0.002* 0.552 
RE   61±45 77±38 61±42 80±31 0.091 0.013* 0.714 
MH   64±16 72±10 64±15 70±15 0.006* 0.081 0.685 
PCS  47±10 48±9 47±9 48±9 0.221 0.128 0.955 
MCS  40±9 43±9 40±10 43±10 0.026* 0.009* 0.981 
Values are mean and SD.* Statistically significant with a p-value < 0.05. WG; women group, MG; men group. 
Dimensions of SF-36; PF; physical functioning, RP; role-physical, BP; bodily pain, GH; general health, VT; vitality, 
SF; social functioning, RE; role-emotional, MH; mental health. Domains of SF-36; PCS; Physical Components 
Summary, MCS; Mental Components Summary 
Hemodynamic assessments 
Between the groups there were no differences in SBP, DBP as well as HR at 
baseline or at the end of study. Within the WG there were improvements in SBP (p= 
0.010) and DBP (p<0.001), but no difference was seen in HR (p=0.261) at the end of 
study. There was also improvement within the MG in DBP (p=0.021) at end of study, 
but no differences were seen in SBP (p=0.057) or HR (p=0.869), Table XV. 
Table XV. Changes in systolic, diastolic blood pressure and heart rate over time 
  
WG  WG MG MG With-in With-in 
Between  
groups 
n=37 n=37  n=34  n=34  WG MG  
Baseline 
End of 
study 
Baseline 
End of 
study 
End of 
study 
End of 
study 
End of 
study 
        p-value p-value p-value 
SBP,mmHg 138±19 129±17 133±14 129±13 0.010* 0.057 0.253 
DBP,mmHg 82±10 75±11 80±9 76±9 <0.001* 0.021* 0.092 
HR/minute 63±11 60±12 63±18 62±16 0.261 0.869 0.560 
 Values are mean and SD. * Statistically significant with a p-value < 0.05. WG; women group, MG; men group,  
mmHg; millimetre of mercury, SBP; systolic blood pressure, DBP; diastolic blood pressure, HR; heart rate.  
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DISCUSSION  
 
Our main findings were that MediYoga improved HRQoL among patients with PAF, 
especially their mental health. Moreover, systolic blood pressure decreased after 
performing MediYoga. No gender differences were found regarding the effects of 
performing MediYoga. However, both men and women improved their mental health 
as well as diastolic blood pressure. The patients also described how they had been 
provided with a tool, in MediYoga, to handle emotions as well as symptoms. They 
also experienced a decrease in palpitations.  
There is substantial evidence from the literature that many patients with AF 
experience reduced HRQoL (57, 58, 153, 154) regarding both physical and mental 
health. Interventional (such as ablation) (155) and medical treatments (such as 
rhythm/rate regulation) may improve HRQoL (155, 156), but, yet, there are adverse 
events and side effects of these treatments which afflict the patients. Thus, there is 
room for introducing self-management programs for patients with AF as an additional 
treatment.  
We have shown that patients with PAF, Papers I-II as well as Paper IV, improved 
their mental health (MCS, SF-36) after performing MediYoga. There was also an 
improvement in bodily pain, Paper II, which may be related to the movements in the 
MediYoga program that contribute to enhancing bodily functions. Improvements in 
bodily functions were also described in Paper III. This is in accord with the literature 
indicating that improved mental health may have a positive impact on physical health 
(53). Moreover, the social life of patients with PAF may have deteriorated (59). The 
results of our study, with increased social function (SF) may indicate improvement in 
their social situation.  
We did not find any differences between the three groups (MediYoga, control and 
relaxation group) in Paper II regarding the two HRQoL questionnaires (SF-36 and 
ASTA). However, close scrutiny of the changes in the sub-scales of SF-36, over time 
in the different groups, reveals that all sub-scales increased in the MediYoga group. 
In addition, the sub-scales showed no change, some slight increase or a trend to 
decrease in the control- and the relaxation groups. However, this is a small study 
and the changes may be different in a larger population.  
Moreover, the questionnaire ASTA measures symptoms related to HRQoL, which in 
Paper II showed no change in the MediYoga group. In contrast, the patients in Paper 
III reported a reduction in their palpitation symptoms. Also, the sub-scales in ASTA 
showed greater improvement in the control group, and to some extent in the 
relaxation group. There was no improvement in the MediYoga group. A close 
examination of the estimated scores revealed that the MediYoga group may have 
lower symptom-related HRQoL scores, in ASTA, than the other groups (the lower 
estimated scores in ASTA indicates better HRQoL). This shows that the MediYoga 
patients experienced less symptoms than the other two groups. Although one of the 
inclusion criteria was “symptomatic PAF”, the number of symptomatic episodes can 
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differ at baseline in the groups. This may explain why the MediYoga group had less 
symptoms at baseline and that there were no changes over time. The changes in the 
control group may differ because of receiving new medication, with reduction in 
symptoms, as well as the knowledge of being able to participate in MediYoga 
sessions after the study.  
The results from Papers I-II and IV are in accordance with the literature, where 
patients with PAF report a lower HRQoL than the normal population, in Sweden, and 
to the same degree or worse as other chronic heart conditions (57). There were no 
gender differences in HRQoL at the end of the study, in Paper IV, but mental health 
outcome improved within both groups. Previous studies have found that women with 
AF report an overall lower HRQoL than men (38, 157). This is not with the case in 
our study, where both genders rated their mental health as low at baseline. Our 
findings also differ from those of Paquette et al. (57). In the latter study women more 
often had lower physical scores than men whereas we found high physical scores in 
both genders. In addition, both women and men had lower mental health outcomes 
than physical outcomes compared to Paquette et al. It may be that the patients in 
our study, both genders, had more symptomatic AF, which affected their mental 
health. In addition, men experienced the same symptoms as women and this may 
indicate that both genders require a complementary treatment, as a part of a self-
management.  
Hypertension is a risk factor in the incidence of both AF and the recurrence of AF (6-
8). Our results in Papers I-II and IV show that systolic and diastolic blood pressure 
decreased after performing MediYoga. This is in agreement with other studies using 
yoga, which have evaluated blood pressure (158-161). The heart rate decreased 
after performing MediYoga in Paper I, but not in Papers II and IV. Other studies have 
found that performing yoga decreases heart rate (108, 110). As we included only 
patients with symptomatic PAF in Paper II, the defaulted reduction in heart rate in 
Papers II and IV may be explained by the burden of episodic AF; the heart rate may 
have been higher in Papers II and IV than in Paper I. Medical treatment for patients 
with AF has evolved and improved over the last years. Patients may have been 
better stabilized by medical treatments in Papers II and IV than in Paper I. There is 
also a diversity of age among the participants in Papers I-II in comparison to the 
median age of AF (1). Our participants are younger, which is reflected in that many 
of them were still working and perhaps more affected by the AF episodes.  
There was no improvement in NT-proBNP within or between any of the groups in 
Paper II, which may be related to the fact that NT-proBNP may only change to a 
limited degree over a three-month period. Cardiac biomarkers, such as NT-proBNP 
are also associated with the amount of episodes of AF (162). A recent study 
describes a normal value of NT-proBNP as 125 ng/L (163). In our study, the values 
of NT-proBNP were from 175 to 285 ng/L which suggesting that the patients in all 
groups had episodes of AF; this was however, not further evaluated . 
Patients with PAF seeks complementary therapies in the approach for example to 
self-manage symptoms as a self-care (95). In this context, a few studies have been 
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evaluating complementary therapies to manage symptoms and increase HRQoL. 
One study found that yoga may reduce episodes of AF as well as decrease anxiety 
and depression (109). This is an important finding though depression is connected to 
the incidence of AF (23). Similarly, a brief cognitive behavioural therapy program 
showed improved results in HRQoL among patients with PAF (69). However, the 
latter study evaluated patients together with their spouses, and the program must be 
conducted with educated instructors at specified sites. This may exclude single 
patients and also deprive them of the freedom to use a program whenever and 
wherever desired. Our studies suggest a program which, after short instruction, may 
be performed independent of instructors or spouses. It has also been described by 
patients, in Paper III, as easy to carry out. It can also be used in different venues. 
In Paper III, the patients reported that MediYoga supported them in handling 
emotions, such as anxiety and worry, as well as in reducing symptoms, which in this 
context may be related to improved mental health. So far, studies have evaluated 
patients’ concerns about living with AF (59, 61, 67, 164-166). These concerns 
include a lack of information about the disease and symptoms, knowledge about 
medications as well as how to manage symptoms and emotions. Guidelines have 
been developed as to how to support patients with AF in medical care (167). 
Moreover, the literature concludes that managing the risk of developing AF or 
reducing the risk of cardiovascular events requires tailoring the management of the 
modifiable risk factors associated with AF (36). Also, structured care and nurse-led 
strategies have shown improvements in the management of patients with AF (70, 
168). Even if the literature suggests that there is a need for interventions and 
practical tools, such as self-management, that assist patients in managing their 
emotions in/or between episodes of AF, (67, 68) none of the above guidelines and 
strategies include self-management programs. Health care is going in a direction 
whereas nurse allied and caring science recommends an individual holistic approach 
(46, 47) when caring for patients, thus, to improve patients´ outcome as well as 
improve their QoL. In relation to patients with PAF and existing healthcare 
treatments, thus, is far from responding to the individual desires, needs as well as 
how they can manage their illness. It is therefore important to provide support and 
assistance to this population in their health process. Thus, in this context of an 
extended self-management programs which support the patients with tools to 
manage their symptoms.  
Our results, in Paper III, show that MediYoga provided patients with a tool enabling 
them to reduce their fear and better cope with emotions elicited by symptoms. 
Patients also reported attaining an increased awareness of bodily functions and the 
ability to influence them. As the definition of self-management includes, “the ability to 
manage symptoms and life-style behaviours” we suggest that MediYoga may play 
an important role in this context. 
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METHODOLOGICAL CONSIDERATIONS 
 
The literature indicates the importance of including a disease-specific questionnaire 
when measuring HRQoL (50). At the start of study I (paper I), we found disease-
specific questionnaires, involving AF, in English but not in Swedish. When planning 
study II (paper II), we found a new validated disease-specific questionnaire, ASTA, 
which was included, as a complement to SF-36, which includes symptom-related 
outcomes.  
In Paper I we included patients with a diagnosis of PAF whereas in Paper II we 
added symptomatic PAF as an inclusion criterion. PAF symptoms affect HRQoL, 
and to strengthen the evaluation of HRQoL over time it seemed more appropriate to 
include only patients with symptomatic PAF. Episodes of AF have not been 
monitored in Papers I and II. Thus, we cannot make any statements as to whether 
MediYoga had any effects on AF recurrence. In Papers I and II there is a 
discrepancy in the number of screened patients. This can be partly explained by the 
addition of symptomatic PAF as an inclusion criterion, and diabetes mellitus and 
untreated hyperthyroidism as exclusion criteria in Paper II.   
Group sessions with patients suffering from the same condition may increase 
participants’ HRQoL (169). In order to avoid this effect, we conducted a study with 
three-arms, i.e. yoga/relaxation/control, in Paper II. To our knowledge there is only 
one other study using yoga and evaluating HRQoL among patients with PAF. The 
current thesis may serve to strengthen the evidence of the positive impact of yoga 
on HRQoL.  
In this thesis, we used a yoga form, MediYoga that is performed with calm 
movements. It can be conducted sitting in a chair, lying or sitting on a blanket and 
can be used in different venues. Because of its simplicity, persons of all ages and 
with different diseases are able to perform this form of yoga. It is also easily 
implemented in clinical settings and, in addition, the patients can perform the yoga 
program by themselves after training. The amount of time spent performing yoga in 
group sessions was based on recommendations from the literature and the 
Kaivalyadhama Centre, India, which the author visited for research purposes. The 
reason to select relaxation with music is that music therapy seems to have positive 
effects in HRQoL, blood pressure and heart rate (98, 99) . Also, the program could 
be conducted in the same environment as the yoga sessions, indifferent times. The 
amount of time in the group sessions, 30 minutes, are described to be sufficient 
(170). Thus, we tried to separate the effects of yoga from other methods with a 
similar effect. 
In Paper III, we included 12 patients to provide in-depth material and contribute to 
trustworthiness. The interviews were conducted between 2015 and 2017, a long 
period in this context. Paper II’s study was in progress during this time. The outcome 
may have been different if the time-span had been shorter. However, we achieved a 
sufficient level of information power. As the principal author lacked experience in the 
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field of research interviews, the other two authors, with experience, also conducted 
interviews (three each). The interviews were transcribed verbatim and then checked 
by the principal author. To ensure confirmability the texts were then analysed and 
discussed several times by all the authors. In accord with the description given by 
Graneheim, Lindgren and Lundman (151), using a manifest approach, the data were 
identified in terms of categories. The literature recommends that interviews should 
take place a short time after an intervention, to ensure that the information is fresh 
(150). In Paper III, we interviewed the participants within four weeks of the final visit 
in the randomized study, Paper II. We discussed using a different approach, such as 
phenomenological, but the latter is a descriptive method in which the participants 
describe the occurrence of a phenomenon in the context of their life-world. This were 
not our purpose. Our intention was to describe how yoga affected the participants 
and how they experienced performing yoga. We concluded that semi-structured 
interviews and content analysis would be the most appropriate methods in this 
context.  
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CONCLUSIONS 
 
• MediYoga improved HRQoL parameters, especially mental health, and decreased   
blood pressure among patients with symptomatic PAF. MediYoga may be adopted 
as a part of self-management program, combined with standard treatment, to reduce 
symptoms, such as anxiety and worry. 
 
• Experiences and perceptions of MediYoga described decreased symptoms and 
MediYoga was perceived as an accessible tool to manage emotions related to 
episodes of AF. MediYoga integrates physical, mental and spiritual components, 
which may assist in achieving a holistic approach. Using MediYoga as a self-
management program may help patients manage their situation, which may lead to 
an improvement in HRQoL.  
 
 
• No gender differences were observed. However, MediYoga appears to improve 
mental health in both men and women.  
 
• An improved mental health may help to achieve improved physical health and 
therefore an overall improved balance in life. With this knowledge we suggest that 
MediYoga may be a part of a self-management program for patients with PAF. 
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CLINICAL IMPLICATIONS  
 
To be provided with a tool to handle symptoms and emotions, which occur during or 
between the episodes of AF, may contribute to an increased knowledge about self-
care and self-management and therefore an improved feeling of security. 
Improved mental health and reduced blood pressure among patients with 
paroxysmal atrial fibrillation, after performing MediYoga, may improve their social 
situation. 
The MediYoga program is suitable for patients with PAF as it involves movements, 
deep breathing and meditation, possible regardless of age. We believe that this yoga 
form can be implemented in health care due to its simplicity and be performed 
generally amongst the PAF population.  
MediYoga, as a self-management program, may be a complementary therapy for 
patients with symptomatic PAF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
LIMITATIONS AND FUTURE PERSPECTIVES 
 
These data have limitations due to a short follow-up and no evaluation of whether 
MediYoga affects the number of symptomatic AF episodes. A longer follow-up is 
therefore warranted to see if the positive effects on HRQoL are maintained. Heart 
rhythm monitoring should be performed to see if MediYoga reduces the number of 
AF attacks. Further, an evaluation of hospitalization and health care costs are 
necessary to assess the cost effectiveness of MediYoga. 
Our results show that the MediYoga resulted in improved social functioning. This is 
an interesting finding and may be further evaluated to see if these improvements are 
maintained.  
Although these data suggest that MediYoga improved mental health in PAF patients, 
larger randomized studies are warranted to compare MediYoga with other life-style 
interventions, for example, cognitive behavioural therapies, known to increase 
HRQoL.  
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SVENSK SAMMANFATTNING 
INLEDNING 
Förmaksflimmer (FF) är den vanligaste hjärtarytmin i den vuxna befolkningen. 
Utöver ålder och kön är högt blodtryck den viktigaste riskfaktorn för insjuknande av 
FF. Flera biomarkörer inklusive NT-proBNP och Troponin har visat sig vara relaterat 
till FF. Symtom förekommer ofta i form av hjärtklappning, tryck över bröstet, 
andfåddhet, yrsel, ångest och oro. Standardbehandlingen för FF är symtomlindring 
och består av rytm- och frekvensreglerande läkemedel, elkonventering samt 
ablation. Alternativa metoder bör tillföras, som till exempel förändringar av 
livsstilsfaktorer. Skillnader mellan könen som har FF är bland annat att kvinnor är 
äldre och har mer hypertoni samt hjärtsvikt. 
FF är associerad med nedsatt hälsorelaterad livskvalité. Symtom från episoder av 
FF kan påverka sociala situationer och arbetsrutiner och det förekommer ofta 
känslor av ångest och depression. I avseende av könsskillnader har studier visat att 
kvinnor skattar sämre livskvalité än män. 
Patienter med FF söker komplementära behandlingar för att kunna minska sina 
symtom och öka sin livskvalité. Yoga kan ses som en av dessa komplementära 
behandlingar och beskrivs att balansera det parasympatiska och sympatiska 
nervsystemet, sänka blodtryck, hjärtfrekvens samt NT-proBNP. Yoga har också visat 
sig ha effekt på upplevelser av stress och HRQoL. 
Litteraturen beskriver olika ”self-management program” som består av utbildning, 
symtom monitorering, medicinsk följsamhet, livsstil etc. Dessa program skräddarsys, 
utvärderas och genomförs till vad som behövs för att leva med och hantera 
sjukdomen.  
Det övergripande målet inom omvårdnad och vårdvetenskap är att stödja och stärka 
patienternas hälsa och processer med tanke på hälsa, sjukdom och lidande. I denna 
process är det viktigt att det behandlas utifrån patientens uppfattning hur sjukdomen 
påverkar deras upplevelse av mening och sammanhang.  
Det övergripande syftet med denna avhandling var att studera effekter, upplevelser 
samt erfarenheter av MediYoga hos patienter med paroxysmalt förmaksflimmer 
samt att studera könsskillnader.  
METOD OCH RESULTAT 
Studie I: Detta är en randomiserad kontrollerad pilotstudie med 80 patienter som 
randomiserades till yogagrupp, n=40, eller kontrollgrupp, n=40 på 
Universitetssjukhus, Stockholm, Sverige. MediYoga gruppen utförde yoga en 
timme/vecka i 12 veckor. Hälsorelaterat livskvalitéfrågeformulär (SF-36, EQ - 5D 
visuell analog skala), blodtryck och hjärtfrekvens mättes vid studiestart och vid 
studiens slut. Resultaten visar att hälsorelaterad livskvalité förbättrades i 
yogagruppen och blodtryck samt hjärtfrekvens sjönk i jämförelse med 
kontrollgruppen. 
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Studie II: I denna studie med stratifiering av kön, randomiserades 132 patienter, med 
symtomatisk PAF, till MediYoga grupp (n = 44), avkoppling (n = 44) och 
kontrollgrupp (n = 44). MediYoga gruppen utförde yoga en timme/vecka i 12 veckor.  
Hälsorelaterad livskvalité (SF-36, ASTA), blodtryck, hjärtfrekvens samt NT-proBNP 
mättes vid studiestart och i slutet av studien. Resultaten visade inga skillnader i 
ASTA och SF-36 mellan grupperna. Dock förbättrades hälsorelaterad livskvalité, SF-
36, inom MediYoga gruppen. Både systoliskt och diastoliskt blodtryck minskade i 
gruppen som utförde MediYoga jämfört med kontrollgruppen, men det var ingen 
skillnad jämfört med avkopplingsgruppen. Det fanns inga skillnader i hjärtfrekvens 
och NT-proBNP mellan eller inom grupperna efter 12 veckor. 
Studie III: Detta är en studie med en kvalitativ design som genomfördes med 
individuella semistrukturerade intervjuer. Studien genomfördes med 12 deltagare (7 
män och 5 kvinnor, medelålder 63,5) som hade deltagit i MediYoga gruppen i studie 
II. Data analyserades med kvalitativ innehållsanalys med en induktiv metod och ett 
manifest förhållningssätt. Tre kategorier identifierades i analysen; ”En tid för en 
känsla av existens och närvaro”, ”Ett sätt att få välbefinnande och ökad 
medvetenhet” och ”Tillgång till ett verktyg för att få viljestyrka och lindra symtom” 
 
Studie IV: Detta är en studie med en jämförande design mellan könen som hade 
utfört MediYoga. I denna studie analyserades enbart data från yogagrupperna 
(kvinnor n = 37, män n = 34). Data (dvs. hälsorelaterad livskvalité [SF-36], blodtryck 
och hjärtfrekvens) samlades vid studiestart och studiens slut. Det fanns inga 
skillnader mellan gruppen kvinnor eller män i SF-36 vid slutet av studien, emellertid, 
fanns förbättring med i gruppen kvinnor i subskalorna vitalitet, social funktion, 
psykisk hälsa och i domänen mental komponent. Hos män förbättrades subskalorna 
roll-fysisk, kroppslig smärta, allmän hälsa, vitalitet, social funktion, roll-känsla och 
domän mental komponent (SF-36). Det fanns inga skillnader mellan grupperna i 
systoliskt och diastoliskt blodtryck samt hjärtfrekvens i slutet av studien. Inom 
kvinnogruppen observerades skillnader i systoliskt och diastoliskt blodtryck, men 
ingen skillnad sågs i hjärtfrekvens. Inom gruppen med män förbättrades diastoliskt 
blodtryck men inga skillnader sågs i systoliskt blodtryck eller hjärtfrekvens. 
SLUTSATS 
MediYoga förbättrar HRQoL samt blodtryck bland patienter med PAF. Dessutom har 
både kvinnor och män fördelar med att utföra MediYoga. Patienter beskriver också 
att MediYoga är ett tillgängligt verktyg att hantera känslor och symtom. MediYoga 
kan vara en del av ett ”self-management” program, som ett komplement till 
standardbehandling, hos patienter med PAF. 
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Supplement I.  
Mediyoga program 
The program started with the patients lying on their back or sitting in a chair and 
taking long deep breaths in through the nose. This was performed for 11 minutes. 
Then followed Movement One for three minutes: back flex, in which the patients 
sat cross-legged or in a chair. Their backs were straight, their hands on their outer 
ankles if on the floor, and on their kneecaps when sitting in a chair. The movement 
was performed by pushing the hips forward so that the body was arched. The 
shoulders were left behind so that the chest could open. Then the hip and pelvis 
rolled backward so that the spine curved. The chin was kept still. Deep breathes 
were taken during the movement, in when rolled forward/up and out when rolled 
backward. Rest for one minute. 
 
Movement Two lasted 3-11 minutes: The patients sat with their legs under them, 
or on their heels if sitting in a chair. Their back was straight, the chin slightly retracted 
and hands interlocked. Arms were stretched above the head and the elbows locked. 
Deep breathing was carried out during the session followed by a one-minute rest. 
Movement Three was a mantra meditation. Sitting cross-legged, or in a chair, with 
the left hand on the breastbone, right hand over left. Relaxed in the shoulders, 
elbows and jaws with closed eyes, focusing on the heart and listening to, or singing 
along with, a yogi mantra for the heart, which was playing in the background. 
Those three movements were interspersed with the following movements:  
 
1. Back Twist for three minutes. Hands up on the shoulders, fingers, and thumbs 
back. Elbows out to the sides up to shoulder height. The chin slightly indented. 
During inhalation, the upper body was turned to the left. During exhalation, the body 
was turned to the right. The chin was constantly in line with the breastbone and this 
was followed by resting for one minute.  
2. Back Bending for three minutes. Hands on the shoulders, as in Movement 1. 
While inhaling, the upper body was bent down on the left side toward the floor. At the 
same time an attempt was made to point the right elbow up toward the ceiling. 
During exhalation, the movement was in the other direction down to the right. 
Resting for one minute. 
3. Neck Rolling for approximately two minutes. Sitting with a straight back, the 
jaw was relaxed, letting the chin fall to the chest. The chin was moved slowly 
clockwise in a large circle. One whole circle took about 10 seconds. After 10-15 laps 
the direction changed and 10-15 laps were performed in the other direction. The 
head was then slowly straightened up and a rest was taken. 
The program was ended with 5-10 minutes of relaxation. 
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Supplement II. 
YOGA PROGRAM MYPAF 
DEEP BREATHING  
Sit on a chair or lie on your stomach or a thick blanket. Take deep long breaths 
through your nose. Inhale all the way up to the clavicles through expanding the 
stomach, lungs and chest. Exhale and feel your stomach and chest drop again. The 
expiration is passive, and the inhalation is active. Rest between ex- and inhalation. 
SUFI CIRCLES  
Adopt an easy meditation position and clasp your knees. Clockwise in a circular 
motion rotate your abdomen, pelvis and hips. Strive to keep your head centred in the 
middle. Change direction after 1 to 3 min and rotate counter-clockwise for an 
additional 1-3 min. Long deep breaths throughout the exercise and rest seated after 
the exercise. 
TOWARDS BEND 
Sit with legs outstretched in front of you and lean your torso straight up toward your 
knees. Stay as deep you can, in this position, and take long deep breaths. Relax 
your neck and after 1-3 minutes come up gently and rest sitting.  
BUTTERFLY 
Sit in an easy meditation position and position the soles of your feet against each 
other. Grab your feet, with your hands, and pull your heels toward your body. With a 
straight back start to rock your knees up and down. Try to come down as close to 
the floor as possible with your knees. Long deep breathes for 1-3 minutes. Rest. 
HIP LIFT 
Lie on your back and put the soles of your feet on the floor whilst pulling your heels 
as close as possible to your buttocks. Take hold of your ankles, push up with your 
hips and abdomen as high as you can towards the ceiling while inhaling. Breathe out 
with your buttocks down on the floor again.  
CAT and COW  
Standing on all fours with feet together and a hip width between your knees. 
Shoulders should be a palm width apart. Hollow down your back, lift your head as 
high as you can and breathe in at the same time. Exhale, pull your chin toward your 
chest and push back up towards the ceiling. Up and down this way for 1-3 minutes.  
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BABY POSE  
Resting in a baby pose for two minutes. Strive to bring your buttocks down against 
your heels and your forehead on the floor. Long deep breaths. 
NECK ROLLING  
Sit in easy meditation position. Lower your chin towards your chest with a straight 
back and stretched neck. Slowly pull your chin along the right collarbone up to the 
right shoulder and, from there, the chin up through the air down to the left shoulder, 
down along the left collarbone, back to the starting point and continue in the same 
direction. Breathe out through your nose when your chin rolls down over your chest 
and breathe in through your nose when your head is moving backward. Relax your 
shoulders and jaw and let your chin drop. Change direction after 10-15 turns 
clockwise and make 10-15 equally slow turns back the other way. A lap should take 
about 10 seconds there should not be any pain in your neck. 
STRETCH  
Allow yourself to rest and relax for a while. Stop taking deep breaths and allow 
yourself to breathe naturally. Stretch gently and place the left foot on the right knee, 
pull your knee down toward the right while you rotate your upper body to the left. 
Stretch and switch side i.e., the right foot on the left knee for a minute. 
MEDITATION  
Sit in an easy meditation position (on a chair). With a straight back and stretched 
neck, close your eyes and place the focus on the 3rd eye. Your hands rest gently 
against your knees or thighs. Repeat the following mantra: according to instructions 
of SA-TA-NA-MA for 11 minutes. Forefinger to thumb presses against each other 
when saying SA. Then press thumb and the middle finger on TA. On NA press you 
thumb to ring finger top. On MA press your thumb to little finger tip. Repeat this for 
11 minutes. 
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Supplement III. 
Question - guide and follow-up questions 
 
What were your thoughts about yoga before you began this project?  
 
Negative expectations?  
Positive expectations?  
Ambivalent perceptions/experiences about yoga?  
 
Tell us about a yoga session you were in!   
 
Can you describe what happened?  
Positive effects? Physically, mentally.  
Negative effects? Physically, mentally.  
Can you describe the experience?  
Why do you think you experienced this?  
 
 
Was there a moment in the yoga sessions that you experienced in any special 
way?  
 
How did you experience yourself before the yoga session?  
  
How did you experience yourself after the yoga session?  
 
What are your views on yoga now?  
 
Summarize your experience of yoga.  
 
 
 
 
 
